{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T16:04:22Z","timestamp":1790352262979,"version":"4.1.0"},"reference-count":61,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T00:00:00Z","timestamp":1787961600000},"content-version":"am","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Health-system pharmacists play a crucial role in monitoring the pharmaceutical pipeline to manage formularies, allocate resources, and optimize clinical programs for new therapies. This article aims to support pharmacists by sharing new and anticipated novel drug approvals.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>Selected drug approvals anticipated in the 12-month period covering the third quarter of 2026 through the second quarter of 2027 are reviewed. The analysis emphasizes drugs expected to have significant clinical and financial impact in hospitals and clinics selected from 66 novel drugs awaiting US Food and Drug Administration (FDA) approval. This year\u2019s pipeline features novel therapies for various disease states including rare and inherited genetic disorders, immunology and inflammatory diseases, and continued advancements in both targeted oncology therapies and gene therapies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Novel therapies continue to strengthen the current drug pipeline.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ajhp\/zxag244","type":"journal-article","created":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T20:30:17Z","timestamp":1788035417000},"source":"Crossref","is-referenced-by-count":0,"title":["Recent and anticipated novel drug approvals (3Q 2026 through 2Q 2027)"],"prefix":"10.1093","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4403-7599","authenticated-orcid":false,"given":"Lauren","family":"Endriukaitis","sequence":"first","affiliation":[{"name":"Northwestern Medicine , Chicago, IL ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Han","sequence":"additional","affiliation":[{"name":"Northwestern Medicine , Chicago, IL ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thuy","family":"Tran","sequence":"additional","affiliation":[{"name":"Northwestern Medicine , Chicago, IL ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"Choi","sequence":"additional","affiliation":[{"name":"Northwestern Medicine , Chicago, IL ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew M","family":"Levitsky","sequence":"additional","affiliation":[{"name":"BCPS, IPD Analytics , Aventura, FL ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew H","family":"Rim","sequence":"additional","affiliation":[{"name":"Northwestern Medicine , Chicago, IL ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,8,29]]},"reference":[{"key":"2026092511161576300_zxag244-B1","author":"Brand and Biosimilar Pipeline Database [proprietary data]"},{"key":"2026092511161576300_zxag244-B2","doi-asserted-by":"publisher","DOI":"10.1093\/ajhp\/zxag179","article-title":"Recent and anticipated novel drug approvals (Q2 2026 through Q1 2027)","author":"Joseph","journal-title":"Am J Health-Syst Pharm"},{"key":"2026092511161576300_zxag244-B3","doi-asserted-by":"publisher","DOI":"10.1093\/ajhp\/zxag061","article-title":"Recent and anticipated novel drug approvals (1Q 2026 through 4Q 2026)","author":"Dean","journal-title":"Am J Health-Syst Pharm"},{"key":"2026092511161576300_zxag244-B4","doi-asserted-by":"publisher","DOI":"10.1093\/ajhp\/zxaf338","article-title":"Recent and anticipated novel drug approvals (4Q 2025 through 3Q 2026)","author":"Karas","journal-title":"Am J Health-Syst Pharm"},{"key":"2026092511161576300_zxag244-B5","author":"US Food and Drug Administration"},{"key":"2026092511161576300_zxag244-B6","author":"Ultragenyx Pharmaceutical Inc"},{"key":"2026092511161576300_zxag244-B7","author":"Ultragenyx"},{"key":"2026092511161576300_zxag244-B8","author":"US Food and Drug Administration"},{"key":"2026092511161576300_zxag244-B9","author":"US Food and Drug Administration"},{"key":"2026092511161576300_zxag244-B10","author":"US Food and Drug Administration"},{"key":"2026092511161576300_zxag244-B11","author":"Merck"},{"key":"2026092511161576300_zxag244-B12","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1200\/JCO-25-02142","article-title":"Ifinatamab deruxtecan in patients with extensive-stage small cell lung cancer: primary analysis of the phase II IDeate-Lung01 trial","volume":"44","author":"Rudin","year":"2026","journal-title":"J Clin Oncol"},{"key":"2026092511161576300_zxag244-B13","author":"Lin"},{"key":"2026092511161576300_zxag244-B14","author":"OncLive"},{"key":"2026092511161576300_zxag244-B15","author":"Inhibrx Biosciences"},{"key":"2026092511161576300_zxag244-B16","author":"Inhibrx Biosciences"},{"key":"2026092511161576300_zxag244-B17","author":"Immunome"},{"issue":"16_suppl","key":"2026092511161576300_zxag244-B18","doi-asserted-by":"publisher","first-page":"11506","DOI":"10.1200\/JCO.2026.44.16_suppl.11506","article-title":"RINGSIDE: a phase 3 randomized, placebo-controlled trial of varegacestat for treatment of progressing desmoid tumors","volume":"44","author":"Gounder","year":"2026","journal-title":"J Clin Oncol"},{"key":"2026092511161576300_zxag244-B19","author":"US Food and Drug Administration"},{"key":"2026092511161576300_zxag244-B20","author":"Cortese"},{"key":"2026092511161576300_zxag244-B21","author":"Spero Therapeutics"},{"key":"2026092511161576300_zxag244-B22","author":"Ophthalmology Times"},{"key":"2026092511161576300_zxag244-B23","author":"AstraZeneca"},{"key":"2026092511161576300_zxag244-B24","author":"Shionogi"},{"issue":"19","key":"2026092511161576300_zxag244-B25","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1056\/NEJMoa2509306","article-title":"Ensitrelvir for covid-19 postexposure prophylaxis in household contacts","volume":"394","author":"Hayden","year":"2026","journal-title":"N Engl J Med"},{"key":"2026092511161576300_zxag244-B26","author":"US Food and Drug Administration"},{"key":"2026092511161576300_zxag244-B27","author":"Achieve Life Sciences"},{"key":"2026092511161576300_zxag244-B28","author":"Sobi"},{"key":"2026092511161576300_zxag244-B29","author":"American Med Spa Association"},{"key":"2026092511161576300_zxag244-B30","author":"Vertex Pharmaceuticals"},{"key":"2026092511161576300_zxag244-B31","author":"Vertex Pharmaceuticals"},{"key":"2026092511161576300_zxag244-B32","author":"Aircuris"},{"issue":"24","key":"2026092511161576300_zxag244-B33","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1056\/NEJMoa2515131","article-title":"Phase 3 results of bepirovirsen treatment for chronic hepatitis B virus infection.\u202fN","volume":"394","author":"Hou","year":"2026","journal-title":"Engl J Med"},{"key":"2026092511161576300_zxag244-B34","author":"GSK"},{"key":"2026092511161576300_zxag244-B35","author":"Axsome Therapeutics"},{"issue":"7","key":"2026092511161576300_zxag244-B36","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1093\/ajrccm\/aamag215","article-title":"Aroxybutynin and atomoxetine (AD109) for obstructive sleep apnea: a randomized phase 3 trial (SynAIRgy)","volume":"212","author":"Strollo","year":"2026","journal-title":"Am J Respir Crit Care Med"},{"key":"2026092511161576300_zxag244-B37","author":"BridgeBio Pharma, Inc"},{"key":"2026092511161576300_zxag244-B38","author":"Dyne Therapeutics"},{"key":"2026092511161576300_zxag244-B39","author":"Dyne Therapeutics, Inc"},{"issue":"9","key":"2026092511161576300_zxag244-B40","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/S1474-4422(25)00225-X","article-title":"Safety and efficacy of apitegromab in nonambulatory type 2 or type 3 spinal muscular atrophy (SAPPHIRE): a phase 3, double-blind, randomised, placebo-controlled trial","volume":"24","author":"Crawford","year":"2025","journal-title":"Lancet Neurol"},{"key":"2026092511161576300_zxag244-B41","author":"Scholar Rock"},{"key":"2026092511161576300_zxag244-B42","author":"Zydus Therapeutics"},{"key":"2026092511161576300_zxag244-B43","author":"Zydus Therapeutics, Inc"},{"key":"2026092511161576300_zxag244-B44","author":"Outlook Therapeutics Inc"},{"key":"2026092511161576300_zxag244-B45","author":"Belite Bio, Inc"},{"key":"2026092511161576300_zxag244-B46","author":"Sanofi"},{"key":"2026092511161576300_zxag244-B47","author":"Sanofi"},{"issue":"10540","key":"2026092511161576300_zxag244-B48","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1016\/S0140-6736(26)00690-2","article-title":"Efficacy and safety of cemdisiran siRNA in myasthenia gravis (NIMBLE): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"407","author":"Vu","year":"2026","journal-title":"Lancet"},{"key":"2026092511161576300_zxag244-B49","author":"Regeneron Pharmaceuticals Inc"},{"key":"2026092511161576300_zxag244-B50","author":"CeleCor Therapeutics"},{"issue":"15","key":"2026092511161576300_zxag244-B51","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1056\/NEJMoa2513880","article-title":"Asundexian for secondary stroke prevention","volume":"394","author":"Sharma","year":"2026","journal-title":"N Engl J Med"},{"key":"2026092511161576300_zxag244-B52","author":"Bayer"},{"key":"2026092511161576300_zxag244-B53","author":"Novartis"},{"key":"2026092511161576300_zxag244-B54","author":"Mirum Pharmaceuticals, Inc. and Incyte"},{"key":"2026092511161576300_zxag244-B55","author":"Mirum Pharmaceuticals, Inc. and Incyte"},{"key":"2026092511161576300_zxag244-B56","author":"BridgeBio Pharma Inc"},{"key":"2026092511161576300_zxag244-B57","author":"Global Genes"},{"key":"2026092511161576300_zxag244-B58","doi-asserted-by":"publisher","article-title":"Obexelimab for the treatment of IgG4-related disease.\u202fN Engl J Med","author":"Della-Torre","DOI":"10.1056\/NEJMoa2601337"},{"key":"2026092511161576300_zxag244-B59","author":"Zenas BioPharma"},{"issue":"7","key":"2026092511161576300_zxag244-B60","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1001\/jamaneurol.2026.1431","article-title":"Efficacy and safety of ecopipam for Tourette syndrome: a phase 3 randomized clinical trial","volume":"83","author":"Gilbert","year":"2026","journal-title":"JAMA Neurol"},{"key":"2026092511161576300_zxag244-B61","author":"Teva Pharmaceutical Industries Ltd"}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajhp\/advance-article-pdf\/doi\/10.1093\/ajhp\/zxag244\/70870357\/zxag244.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajhp\/advance-article-pdf\/doi\/10.1093\/ajhp\/zxag244\/70870357\/zxag244.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T15:16:25Z","timestamp":1790349385000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/advance-article\/doi\/10.1093\/ajhp\/zxag244\/8776103"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,29]]},"references-count":61,"URL":"https:\/\/doi.org\/10.1093\/ajhp\/zxag244","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,29]]},"article-number":"zxag244"}}